|
HOME
BE INFORMED > About PWS > Get Publications > About PWSA (USA) Board of Directors Adults with PWS Advisory Office Staff MEDICAL > Health Concerns > Medical Alert > Psychiatric > Diet Resources > Growth Hormone RESEARCH > Research Grants > Funded Research > Participants Wanted > Research Topics > Scientific Advisory Board > Clinical Advisory Board GET INVOLVED > Spread Awareness > Become member > Registry SUPPORT > Newly Diagnosis > Non-Medical > For Families > For Providers Advisory Board > For Educators > State Chapters > Links and Resources MEDIA GIVE CONTACT US |
PWSA (USA) Funded Research - Second Year March 2008 EXPRESSION OF FOUR GENES BETWEEN CHROMOSOME 15 BREAKPOINTS BP1 AND BP2 IN
SUBJECTS WITH PRADER-WILLI SYNDROME AND IMPACT ON COGNITIVE AND BEHAVIORAL
MEASURES Second year approved – abstract on progress report on first year follows: Prader-Willi syndrome (PWS) is a complex neurodevelopmental disorder resulting from a paternal chromosome 15q11-q13 deletion in 70% of subjects, uniparental disomy 15 causes PWS in 25% of subjects and the rest are due to imprinting defects or chromosome 15 rearrangements. The deletion can be classified as either a large typical Type I (TI) deletion involving breakpoints BP1 and BP3 or a smaller typical Type II (TII) deletion involving breakpoints BP2 and BP3. The researchers are working to quantify the expression of the four genes, NIPA1, NIPA2, CYFIP1 and GCP5 and correlate with neurodevelopmental parameters (behavioral, cognitive and visual integration measurements) previously reported to differ between the two deletion subtypes in Prader-Willi syndrome individuals. This project allows the investigators to expand their pilot data and analysis. Preliminary analyses of their new data tend to support their hypothesis that changes in expression of these genes, whether due to genetics, epigenetics or chromosomal deletions result in alterations in the behavioral and cognitive parameters of individuals with PWS. They hypothesize that the size of the deletion should also be determined by using, for example aCGH technology, on each subject with the typical deletion to further characterize the size and type of the deletion. The enhanced gene expression patterns will then be correlated with behavior and clinical outcomes (and deletion size) in individuals with PWS. The gene expression patterns will also be compared with maternal disomy and comparison subjects.
edited:03/23/2010 |